Progression of Ano-Genital Intraepithelial Neoplasia and Tumors in Relation to Biomarkers
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 48
Special Issue Editor
Special Issue Information
Dear Colleagues,
Oncological biomarkers are used in clinical practice to predict the progression of invasive cancer and choose the best targeted treatment available. The same has also been recently proposed for intraepithelial neoplasia to avoid unnecessary treatments and to preserve the full function of organs. This is especially true for genital organs to avoid impairing sexual function and fertility. The problem for anal precancerous disease is that it is more difficult to screen and diagnose early enough, because of the extension of the anal mucosa and its visualization.
Cytology and high-risk HPV evidence are insufficient in predicting progression since 70–90% of high-risk HPV become clear without medical intervention before 2 years after infection. The goal of improved screening programs should be to identify the remaining 10–30% of women with high-risk HPV persistency prone to progressive oncological disease. The biomarkers that can be used to address this challenge are markers for persistency like E6 and E7 oncoproteins, the numbers of p16/Ki-67-positive cells in cytological screening tests, the p16/Ki-67 immunoscore in histopathology, and, finally, very promising epigenetic tests. Such epigenetic tests also have the potential to identify progression in diseases not related to HPV infections, based either a) on the methylation of the host cell gene and, as a consequence, the impaired function of tumor suppressor genes of genital epithelial cells; or b) on the promoter methylation of specific regions of the HPV genome itself, such as oncogenes E6 and E7, giving information about its oncogenic activity.
Dr. Attila Louis Major
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- intraepithelial neoplasia: cervical, vaginal, vulvar, anal
- high-risk human papillomavirus (hr HPV)
- cancer biomarkers
- oncoproteins
- P16
- Ki-67
- immunoscore
- epigenetic tests
- methylation
- prediction of cancer progression
- HPV oncogenes E6 and E7
- condyloma acuminata
- condylomata acuminata gigantea (Buschke–Löwenstein tumor)
- molecular, immunologic, and genetic risk factors for persistent and recurrent high-risk HPV infection
- anamnestic risk factors for persistent and recurrent high-risk HPV infection
- non-HPV-related precancer and cancer of ano-genital organs
